Skip to main content

Table 2 Descriptive statistics for ADAS-cog, cognitive test battery, ADCS-ADL and CDR-SB (intent-to-treat cohort)

From: The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease

  Active product Control product P valuea
ADAS-cog    
 Baseline 23.89 ± 9.59 (258) 23.39 ± 9.34 (257) 0.550
 Week 24 25.44 ± 11.56 (220) 24.42 ± 10.95 (208) 0.349
 ∆ week 24 – baseline 1.88 ± 6.44 (218) 1.52 ± 5.63 (207) 0.547 (0.513)
Cognitive Test Battery, z score    
 Baseline 0.08 ± 0.75 (228) −0.02 ± 0.71 (235) 0.153
 Week 24 0.09 ± 0.74 (182) 0.01 ± 0.71 (182) 0.260
 ∆ week 24 – baseline −0.10 ± 0.47 (179) −0.05 ± 0.40 (178) 0.301 (0.323)
ADCS-ADL total score    
 Baseline 57.95 ± 13.36 (265) 57.38 ± 13.37 (262) 0.623
 Week 24 54.66 ± 15.56 (228) 54.15 ± 15.91 (223) 0.731
 ∆ week 24 – baseline −3.74 ± 9.76 (228) −3.66 ± 8.03 (223) 0.926 (0.767)
CDR-SB    
 Baseline 6.18 ± 3.01 (264) 6.45 ± 2.89 (259) 0.296
 Week 24 6.89 ± 3.35 (227) 7.01 ± 3.41 (223) 0.709
 ∆ week 24 – baseline 0.77 ± 1.96 (226) 0.69 ± 1.90 (222) 0.676 (0.500)
  1. Data presented as mean ± standard deviation (n). ADAS-cog, Alzheimer’s Disease Assessment Scale – Cognitive Subscale, ADCS-ADL, Alzheimer’s Disease Cooperative Study Activity of Daily Living; CDR-SB, Clinical Dementia Rating scale – Sum of Boxes; ∆, difference. aP values from t tests, active product versus control product, except for values in parentheses that are P values from mixed model for repeated measures.